Newsletter from Emotra AB (publ)
Göteborg, October 4, 2017

Emotra: fifth EDOR® training seminar carried out yesterday

As we have previously stated, Emotra AB ("Emotra") intends to carry out 12 seminars in various countries in 2017 to train new clinics on the use of EDOR. Our earlier sessions were held in Romania, France, Kazakhstan and Portugal, while this latest session was held in Hungary. Yesterday, October 3, 2017, we held yet another training seminar, this time in Budapest. Which countries these training seminars are held in depends on our ability to arrange them and the participating clinics' ability to spare staff who can attend. We are currently negotiating with a number of clinics in each of the countries where we have completed training seminars. These clinics have informed us that they are interested in purchasing and implementing our equipment for regular use and to be able to participate in a Phase IV follow-up, which Emotra is currently preparing.

Our first four seminars gathered participants from psychiatric clinics and research institutes at larger hospitals, and those who attended yesterday's seminar in Budapest belong to the same category. As with previous training seminars, a number of clinics approached Emotra afterwards to discuss the terms and conditions for acquiring the medical device.
When training seminar attendees want to acquire our equipment, they are not able to simply place an order with us in connection with the training seminar. Acquisition of new equipment has to be decided by their hospital's senior administration or a special procurement function. Through our successful training seminars, we have established contact with a number of clinics that have informed us of their desire to acquire EDOR®. Emotra can offer these clinics a number of different business models to facilitate the decision process for potential buyers.
We are currently discussing the pricing of our products and our rates for clinical follow-up of tested patients.

Comments from Lars-Håkan Thorell, Head of Research
"After all of our completed training seminars, we have seen a keen interest in our product among psychiatric clinics, both in participating in these seminars and in getting started with EDOR®," ***says Lars-Håkan Thorell, Emotra's Head of Research.*** *"We arrange these seminars in collaboration with researchers who participated in our EUDOR-A study and who are already well-acquainted with the method. We at Emotra stress the importance of continuing with our efforts to document the follow-ups of tested patients. We need to collect data from a large number of clinical cases to learn more about the method's precision and reliability. Thanks to our strong scientific base material, the time has come to initiate a so-called Phase IV project. This means that anyone who purchases and uses EDOR® in clinical practice is obligated to both provide us with clinical data about their tested patients and to follow up suicides and suicide attempts among these patients in the following year. These statistics will then be compared with the clinics' suicide statistics from previous years. This Phase IV study will thereby provide information about changes in suicide rates for each participating clinic compared with previous years, as well as compared with clinics that do not yet use EDOR®. We expect this study to prove the real-life advantages of using EDOR®,"* ***Emotra's Head of***

Research continues. *"We are making adjustments to the method and our record-keeping software to enable an easy and rational way of documenting all important follow-up data. Some of the topics of our discussions with these interested clinics concern how this work shall be carried out and how it shall be valued,"* ***Lars-Håkan Thorell concludes****.*

EDOR® will be introduced to psychiatric specialist clinics in Europe as an objective measurement method that aims to supplement traditional, subjective evaluations of suicide risk in routine clinical situations. Testing with EDOR® identifies hyporeactive patients, and since hyporeactivity is a marker for suicide risk, the method provides support in routine evaluations of this risk in patients. Continued studies, first of all an ever-growing documentation from reported tests to a patient follow-up system (Phase IV follow-up), will in the long run increase our understanding of hyporeactivity's importance for suicidal behaviour.

For further information about the Company, please contact: Claes Holmberg, CEO
Telephone: +46 708 25 45 47,
E-mail: claes@emotra.se

Emotra AB (publ) *is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.*